Modulation of the Vasopressin System in Distributive and Cardiogenic Shock: Theoretical Principles and Practical Applications

Comprehensive Summary

This article provides a comprehensive review of the use of arginine vasopressin (AVP) and its analogues as critical alternatives to traditional catecholamines such as norepinephrine in treating circulatory shock. Vasopressin acts on V1a, V1b, and V2 receptors, which acts on smooth vascular muscle, mediate cortisol and insulin release, and promote water reabsorption through aquaporin-2 channels respectively. It also uniquely constricts the efferent and dilates the afferent arterioles in the kidney to promote urine output in shock states. This article uniquely showcases decatecholaminization, or using non-adrenergic vasopressors to reduce the negative effects associated with norepinephrine such as myocardial toxicity, arrhythmias, and immunosuppression and oxidative stress. They also showcased the clinical applications by the shock type. They indicated that larger trials may not reduce overall mortality, but by using AVP, they limit the need for renal replacement therapy, and benefitted patients with less severe shock. In cardiogenic shock it helped patients more prone to arrhythmias or right heart failure from its potential to reduce load on the heart by vasodilation of pulmonary vessels. Post-surgery AVP use provided better hemodynamic stability and fewer post-operative tachyarrhythmias compared with norepinephrine. However, risks should not be taken lightly, and guidelines suggest adding AVP when norepinephrine doses reach 0.25-0.50 ug/kg/min. This should also not be abruptly stopped as it can lead to a rapid drop in blood pressure, or rebound hypotension.

Outcomes and Implications

The use of vasopressin in these scenarios suggests a move from a pure norepinephrine treatment of blood pressure and shock regulation to a more tailored approach, prioritizing “organ-protective” resuscitation. This can be done through using the renal-sparing and anti-arrhythmic properties of vasopressin, which could potentially reduce the incidence of acute kidney injury and cardiac complications in the ICU. This article also touches on precision medicine, using copeptin and artificial intelligence which soon may allow doctors to identify “vasopressin-deficient” patients who would benefit from early intervention.